Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

ClinicalTrials.gov ID: NCT00835237

Public ClinicalTrials.gov record NCT00835237. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.

Study identification

NCT ID
NCT00835237
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,332 participants

Conditions and interventions

Interventions

  • Boostrix® Biological
  • Decavac™ Biological

Biological

Eligibility (public fields only)

Age range
65 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 16, 2009
Primary completion
Jul 22, 2009
Completion
Oct 14, 2009
Last update posted
Jan 2, 2020

2009

United States locations

U.S. sites
24
U.S. states
19
U.S. cities
24
Facility City State ZIP Site status
GSK Investigational Site Tucson Arizona 85741
GSK Investigational Site Los Angeles California 90057
GSK Investigational Site DeLand Florida 32720
GSK Investigational Site West Palm Beach Florida 33409
GSK Investigational Site Stockbridge Georgia 30281
GSK Investigational Site Indianapolis Indiana 46254
GSK Investigational Site Pratt Kansas 67124
GSK Investigational Site Lexington Kentucky 40509
GSK Investigational Site Metairie Louisiana 70006
GSK Investigational Site Columbia Maryland 21045
GSK Investigational Site Elkridge Maryland 21075
GSK Investigational Site Milford Massachusetts 01757
GSK Investigational Site Stevensville Michigan 49127
GSK Investigational Site High Point North Carolina 27262
GSK Investigational Site Wilmington North Carolina 28401
GSK Investigational Site Cleveland Ohio 44122
GSK Investigational Site Mogadore Ohio 44260
GSK Investigational Site Wadsworth Ohio 44281
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Bristol Tennessee 37620
GSK Investigational Site Fort Worth Texas 76135
GSK Investigational Site West Jordan Utah 84088
GSK Investigational Site Williamsburg Virginia 23185
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00835237, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 2, 2020 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00835237 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →